TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05516186

Intervention type: OTHER
Group type: OTHER
Intervention: Scapular-focused exercise protocol with EMGBF
Description: Scapular-focused exercises, based on the dos Santos et al (2021) protocol with the aid of the electromyographic biofeedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular-focused exercise protocol with EMGBF
Description: Scapular-focused exercises, based on the dos Santos et al (2021) protocol with the aid of the electromyographic biofeedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Therapy
Description: manual and exercise therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Therapy
Description: manual and exercise therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Scapular-focused exercise protocol without EMGBF
Description: Scapular-focused exercises, based on the dos Santos et al (2021) protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular-focused exercise protocol without EMGBF
Description: Scapular-focused exercises, based on the dos Santos et al (2021) protocol
Study: NCT04745221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous fecal bacteria
Description: autologous fecal bacteria transplantation
Study: NCT04867343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR020602 injection
Description: HR020602 injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl injection ； remifentanil injection
Description: fentanyl injection + remifentanil injection
Study: NCT05842993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen generator
Description: Patient inhales hydrogen gas for 2 hours per day in the flow rate of 2L/min via nasal cannula by applying hydrogen generator (HZS-2700A, Qingdao Haizhisheng Corp.,LTD, Qingdao, China) for 12 weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Analogue machine
Description: Patient inhales normal air for 2 hours per day in the flow rate of 2L/min via nasal cannula with analogue machine for 12 weeks. This machine has the same appearance as the hydrogen generator.
Study: NCT05773430

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Neurocognitive Training
Description: Only two cognitive domains will be targeted for training (10 hrs of training in each, for a total of 20 hours). Two or more cognitive exercises may be employed within a cognitive domain. These exercises provide both immediate and intermittent feedback and are customized to the participants' individual ability; the difficulty and/or complexity of each game are systematically decreased/increased based on participants' performance to always be challenging, but not overly frustrating. Typically, in an hour session, one exercise (e.g., Mental Map) will be engaged at a time (20-30 minutes) before switching to another exercise (e.g., Hawkeye) in another domain for 20-30 minutes. This helps the participant remain engaged but avoid fatigue.
Study: NCT05279586

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lactulose
Description: all interventions are used in secondary prophylaxis in cirrhotic patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colistin
Description: all interventions are used in secondary prophylaxis in cirrhotic patients
Study: NCT05905484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: A single dose of BEM will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemnifosbuvir (BEM)
Description: A single dose of BEM will be administered.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of matching placebo will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: A single dose of Moxifloxacin will be administered.
Study: NCT05834296

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALZN002 (autologous DCs pulsed with E22W mutant peptide).
Description: The cellular immunotherapy product consists of autologous dendritic cells (DCs) pulsed with a novel amyloid-beta peptide (Aβ1 42) containing a mutation at position 22 from glutamic acid to tryptophan (E22W). This mutation produces novel CD4+ T cell epitopes specific for the mutant E22W peptide that can facilitate an anti-Aβ1-42 antibody response. The activated E22W peptide specific CD4+ T cells license Aβ1-42-specific B cells to secrete anti Aβ1-42 antibodies, resulting in systemic reduction of amyloid and reduction or slowed accumulation of amyloid plaques in the brain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT05799092

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Invasive coronary angiography
Description: As alternative to non-invasive functional testing, invasive coronary angiography will be performed.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive functional test
Description: Standard non-invasive functional testing will be performed.
Study: NCT04501731

Intervention type: OTHER
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: With the TMS session we gather information about nerve fibres from the brain to the hand. It will last around 2 hours and 30 minutes.

Intervention type: OTHER
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: With the TMS session we gather information about nerve fibres from the brain to the hand. It will last around 2 hours and 30 minutes.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: With the MRI scan we will gather information about the brain structure and function. This will last around 30 minutes.

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: With the MRI scan we will gather information about the brain structure and function. This will last around 30 minutes.

Intervention type: OTHER
Intervention: Motor assessment
Description: The motor assessment includes a pegboard game, a grab the alien nose game and measure of your maximum grip force. In total it will last around 30 minutes.

Intervention type: OTHER
Intervention: Motor assessment
Description: The motor assessment includes a pegboard game, a grab the alien nose game and measure of your maximum grip force. In total it will last around 30 minutes.

Intervention type: OTHER
Intervention: Questionnaires
Description: Feasibility, tolerability of such intervention as well as quality of life of PFT survivors will be assessed thanks to questionnaires.
Study: NCT06446297

Intervention type: OTHER
Intervention: Focus Group.
Description: Participants in each focus group will attend a face-to-face (or virtual) meeting that lasts approximately 90 minutes. This will be composed of a briefing period, interview period supported and guided by an interview schedule and finishing with a debrief period. The same process will be followed if individual semi-structured interviews are undertaken.
Study: NCT05973968

Intervention type: DRUG
Intervention: Surufatinib
Description: Taking 28 days as a treatment cycle, the tumor was evaluated by imaging method every 8 weeks (±7 days) in the first 52 weeks, and then every 12 weeks (±7 days) until the disease progression (RECIST1.1) or death (during the treatment of the patient). The treatment and survival status of the tumor after disease progression were recorded.
Study: NCT06446297

Intervention type: OTHER
Intervention: Focus Group.
Description: Participants in each focus group will attend a face-to-face (or virtual) meeting that lasts approximately 90 minutes. This will be composed of a briefing period, interview period supported and guided by an interview schedule and finishing with a debrief period. The same process will be followed if individual semi-structured interviews are undertaken.

Intervention type: OTHER
Intervention: Focus Group.
Description: Participants in each focus group will attend a face-to-face (or virtual) meeting that lasts approximately 90 minutes. This will be composed of a briefing period, interview period supported and guided by an interview schedule and finishing with a debrief period. The same process will be followed if individual semi-structured interviews are undertaken.
Study: NCT06396624

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intervention Group photobiomodulation
Description: Seven spots on child's thorax and two spots on the face will be irradiated with 40s per point of photobiomodulation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The photobiomodulation device will positioned in seven spots on thorax and two in child's face, but it will not emit any time of radiation, since the device will be turned off.
Study: NCT05226299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Supra-threshold and progressive doses of diluted capsaicin via a dosimeter-controlled nebulizer
Description: Participants will be exposured to increasing doses of aerosolized capsaicin (a known cough stimulant) through a dosimeter-controlled nebulizer, while implementing behavioral cough suppression strategies. The concentration of capsaicin will increase incrementally as tolerated, as long as participants are still able to suppress cough. Individual doses will never exceed 1000 micromolar. Cumulative doses per session will never exceed 2000 micromolar. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session. Participants will be encouraged to use cough suppression strategies outside of treatment sessions as much as possible to attempt to suppress cough.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participants will be repeatedly exposed to a saline through a dosimeter-controlled nebulizer during treatment sessions. Participants will attend 12 treatment sessions and be given up to 12 exposures per treatment session.
Study: NCT05700656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib plus capecitabine
Description: Combination therapy with galunisertib plus capecitabine
Study: NCT05141058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavirus-specific T cell (CST)
Description: Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after hematopoietic stem cell transplantation (HSCT).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coronavirus-specific T cell (CST)
Description: Participants will receive donor-derived CSTs for prevention of SARS-CoV-2 infection after HSCT (≥28 days and \<4 months after hematopoietic stem cell transplantation (HSCT).
Study: NCT06384599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VT Cryoablation System
Description: All subjects will receive a cryoablation procedure using the VT Cryoablation System (catheter, stylets, and console)
Study: NCT04672200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group exercise
Description: Weekly group exercises delivered online and face to face
Study: NCT06393205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Naso-Esophageal Tube Feeding
Description: During nasogastric tube feeding, a thin, flexible tube is carefully inserted through one nostril and passed down the throat into the stomach. Once in place, liquid nutrition, medication, or fluids can be administered through the tube, providing essential nutrients and hydration directly to the patient's digestive system. Nasogastric tube feeding may be used temporarily to support patients during acute illness or surgery, or it may be a long-term solution for individuals with chronic conditions that affect their ability to eat normally.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The control group was given enteral nutritional support with Nasogastric Tube Feeding according to the relevant guidelines. Within 4 hours after admission, the placement of the feeding tube was conducted by professional medical staffs and after intubation, the tube was secured to the patient cheek with medical tape. The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patients condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine treatment
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine treatment
Description: Including： Basic treatment, including corresponding control of risk factors and education on healthy lifestyles.~Swallowing training, including lemon ice stimulation, mendelson maneuver, empty swallowing training, and pronunciation training.~Pulmonary function training, including standing training, cough training, and diaphragm muscle training.
Study: NCT04893382

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PlasmaLyte for fluid resuscitation
Description: Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to PlasmaLyte infusion (as clinically prescribed).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ringer's Lactate for fluid resuscitation
Description: Fluid resuscitation is a critical and essential part in the treatment of severely burned patients. Patients randomized for this arm will be submitted to Ringer's Lactate infusion (as clinically prescribed).
Study: NCT05879458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Description: 200 mg QD for 8 weeks followed by 100 mg for 16 weeks
Study: NCT05556174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: periodic lung recruitment maneuvers
Description: lung recruitment maneuvers repeated every 30 minutes
Study: NCT05829018

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mixed meal test
Description: Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mixed meal test
Description: Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mixed meal test
Description: Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mixed meal test
Description: Nutridrink 270 mL 405 kcal, 49 Energy% carbohydrates, 35 Energy% fat, 16 Energy% protein, vitamins, and minerals
Study: NCT06053398

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Intraoperative phenylephrine infusion Phenylephrine infusion to be titrated as needed to target a mean arterial pressure (MAP) \> 65 mm Hg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: Intraoperative norepinephrine infusion Norepinephrine infusion to be titrated as needed to target a MAP \> 65 mm Hg.
Study: NCT05292807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal exposure for memories
Description: Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a past distressing anxiety provoking scenario multiple times while honing in on the most negative aspects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal exposure for future events
Description: Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenario multiple times while honing in on the most negative aspects.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery rescripting for memories
Description: Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a past distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery: First imagining the scenario from a different character perspective that enacts changes in the memories. Second, The will imagine the scenario again from the original perspective along with changes done by the additional character.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery rescripting for future events
Description: Participants in this arm will be asked to decide alongside with the intervention provider (a clinical PhD student or M.A student under the supervision of the principal investigator) to imagine a script based on a future distressing anxiety provoking scenarios one time while honing in on the most negative aspects. Afterwards they will insert changes into the script that try to help them cope in the imagery: First imagining the scenario from a different character perspective that enacts changes in the memories. Second, The will imagine the scenario again from the original perspective along with changes done by the additional character.
Study: NCT04662879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score
Description: ENDPAC is a model to risk-stratify patients with new onset diabetes and hyperglycemia for PDAC. Score is calculated using i) age, ii) change, over past year, in body weight and iii) change, over past year, in glucose/HbA1c values obtained from the electronic medical record.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal imaging
Description: Using computerized tomography (CT) scan or magnetic resonance imaging (MRI), if CT scan is contra-indicated, patients with a high ENDPAC score (\>0) are approached for informed consent to participate in the imaging intervention. Imaging (CT scan) is performed at up to two time points, study baseline and approximately 3-9 months following the first imaging study.
Study: NCT05697016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sivelestat Sodium for Injection
Description: Sivelestat, a specific inhibitor of neutrophil elastase; sodium N-\[2-\[4-(2,2-dimethylpropionyloxy) phenyl-sulfonylaminobenzoyl\]amino-acetate tetrahydrate\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The Placebo
Description: Excipients used for the sivelestat sodium
Study: NCT05134311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PIUR tUS Imaging System
Description: PIUR imaging has developed PIUR Infinity tUS, a 3D freehand tomographic ultrasound system capable of rapid, safe and accurate reconstructive 3D quantifiable vascular imaging.
Study: NCT04904354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcQBlate® Force Sensing Ablation System
Description: Catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein. Additional left and right atrial targets may be ablated as clinically indicated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcQBlate® Force Sensing Ablation System
Description: Catheter ablation of accessible pulmonary veins with the endpoint of creating electrical isolation for each targeted vein. Additional left and right atrial targets may be ablated as clinically indicated.
Study: NCT06371625

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transeversus Thoracic Plane Block (TTPB) and Pectoral Nerves (PECS) Block
Description: The TTP block will be performed in a supine position before general anesthesia. First, a high linear probe of the ultrasound system will be attached at sagittal plane to the sternum and counted from T2 near the clavicle to T5. Then the linear probe will be rotated by 90° and attached between the forth and the fifth costal cartilages connecting at the sternum near nipple. Then, the transversus thoracic muscle and the internal intercostal muscle will be identified. A total of 15 mL of 0.25% bupivacaine will be injected into the interfascial plane, between the transversus thoracic muscle and the internal intercostal muscle between the fourth and fifth costal cartilages connecting at the sternum. Pleural downward displacement will be used as an ultrasound endpoint.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transeversus Thoracic Plane Block (TTPB) and Pectoral Nerves (PECS) Block
Description: The TTP block will be performed in a supine position before general anesthesia. First, a high linear probe of the ultrasound system will be attached at sagittal plane to the sternum and counted from T2 near the clavicle to T5. Then the linear probe will be rotated by 90° and attached between the forth and the fifth costal cartilages connecting at the sternum near nipple. Then, the transversus thoracic muscle and the internal intercostal muscle will be identified. A total of 15 mL of 0.25% bupivacaine will be injected into the interfascial plane, between the transversus thoracic muscle and the internal intercostal muscle between the fourth and fifth costal cartilages connecting at the sternum. Pleural downward displacement will be used as an ultrasound endpoint.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pectoral Nerves (PECS) Block
Description: Patients positioned supine with the ipsilateral arm abducted and externally rotated. The infra-clavicular and axillary regions will be cleaned with chlorhexidine. The skin point of and once the structures are identified with ultrasound, the probe will be positioned under the lateral third of the clavicle. After locating the subclavian artery, the axillary artery and the axillary vein we will move the probe distally towards the axilla, until the pectorals major muscle is identified. We will start counting the ribs, from 1st rib under the axillary artery and maintaining the pectorals major. Serratus anterior muscle cover 2nd, 3rd, 4th rib, this point being the entrance into the anterior axillary line we will use atraumatic needle with extension line and electrode for nerve stimulator (Stimuplex D). We will inject 10ml of 0.25% bupivacaine between the pectorals muscles first, then inject 20ml of 0.25% bupivacaine.
Study: NCT06430593

Intervention type: PROCEDURE
Intervention: low-flow anesthesia
Description: 0,5 l/min \>1 l/min

Intervention type: PROCEDURE
Intervention: low-flow anesthesia
Description: 0,5 l/min \>1 l/min